Stanford cardiologist Joseph Wu, MD, PhD, and instructor Paul Burridge, PhD, have done something similar with stem cells. They’ve devised a way to create large numbers of heart muscle cells called cardiomyocytes from stem cells without using human or animal-derived products, which can vary in composition and concentration among batches. Their technique was published Sunday in Nature Methods. Wu, who is the director of the Stanford Cardiovascular Institute explained to me in an e-mail:
This technique solves an important hurdle for the use of iPS-derived heart cells. In order to fully realize the potential of these cells in drug screening
Dean Third used to look forward to weekends spent refereeing local football matches, and outings with his young family. But now even walking to the end of the road can leave him breathless and exhausted.
For the past four years, the father of four has suffered from dilated cardiomyopathy (DCM), a disease of the heart muscle which causes it to enlarge, affecting its ability to pump blood to the arteries.
The condition afflicts 12,000 people in the UK, and for most sufferers the cause is unknown. If uncontrolled it can be fatal, and patients must adhere strictly to a regime of
Stem cell therapy can regenerate heart muscle in primates, according to a University of Washington study.
The scientists on this and related projects are seeking way to repair hearts weakened by myocardial infarctions.
This all-too-common type of heart attack blocks a major artery and deprives heart muscle of oxygen.
People who survive a severe episode often continue their lives in poor health because their hearts no longer work properly. The researchers hope eventually to restore such failing hearts to normal function.
Their approach uses heart cells created from human embryonic stem cells
The researchers tested the possibility of producing enough of these cardiac muscle
A first-of-its-kind study is just getting underway at University of Minnesota Physicians Heart at Fairview, in Minneapolis. The FDA-approved trial is designed to test the impact of stem cells on restoring the heart’s muscle function in patients suffering from advanced heart failure. The results of the trial could impact the future of health care in the area of heart disease, and may one day save lives (…)
“This trial is designed for heart failure patients in the end stage of heart failure, with no options for treatment,” explained Ganesh Raveendran, M.D., who is the principal investigator of the clinical trial.
New research has found that stem cells derived from human cord blood could be an effective alternative in repairing heart attacks.
At least 20 million people survive heart attacks and strokes every year, according to World Health Organisation estimates, but many have poor life expectancy and require continual costly clinical care. The use of patient’s own stem cells may repair heart attacks, although their benefit may be limited due to scarce availability and ageing. The researchers have found heart muscle-like cells grown using stem cells from human umbilical cord blood could help repair heart muscle cells damaged by a heart